 |
|
|
|
 |
|
|
| Article 1 to 10 out of 31 concerning MediGene AG
|
-
MediGene and Teva sign agreement to commercialize Veregen in Israel
(24 Feb 2010)
MediGene AG has signed a license and supply agreement with Teva Pharmaceutical Industries Ltd. for the supply and commercialization of Veregen(TM) in Israel. Teva will also be responsible for registering the product in Israel, and upon successful ...
-
MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial
(13 Oct 2009)
MediGene AG has successfully completed patient recruitment into its randomized Phase II trial of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer. Results will be available as scheduled in the first six months of 2010. This ...
-
Medigene's RhuDex Clinical Development to Continue Following Feedback from Regulatory Authorities
(07 Oct 2009)
MediGene AG received feedback from the UK MHRA (Medicines and Healthcare products Regulatory Agency) regarding the in-vitro studies conducted with the drug candidate RhuDex(TM) for the treatment of rheumatoid arthritis. These in-vitro studies ...
-
MediGene Receives Further European Patent on EndoTAG-1
(06 Oct 2009)
Patent renews coverage and expands the protected territory
MediGene AG has obtained an extensive patent (no. 1530465) from the European Patent Office on the manufacturing process for the drug candidate EndoTAG(TM)-1. The patent protects the manufacturing process used for EndoTAG(TM)-1, including the drying ...
-
MediGene Signs Agreement with Solvay for the Commercialization of Veregen in Germany, Austria, and Switzerland
(30 Sep 2009)
MediGene AG has signed a license and supply agreement with Solvay Arzneimittel GmbH, the German affiliate of Solvay Pharmaceuticals (Solvay) for the supply and commercialization of Veregen® (formerly Polyphenon E® ointment) in Germany, Austria, and ...
-
MediGene Sharpens Focus through In-House Reorganization
(30 Sep 2009)
Shift of employees and financial resources into clinical development
MediGene AG announced that, as a result of the firm-wide review undertaken by CEO Dr Frank Matthias, the company is to further sharpen its focus and will achieve this through a restructuring. "Within the scope of these measures, MediGene's research ...
-
MediGene AG Receives Marketing Authorization for Veregen in Germany
(11 Sep 2009)
MediGene AG announced that it has received German marketing authorization for Veregen® for the treatment of genital warts from the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM).The ...
-
MediGene receives Positive Assessment on Market Authorisation for Veregen in First European Countries
(14 Jul 2009)
MediGene AG announces that its Marketing Authorisation Application for the medicinal product Veregen® (formerly Polyphenon E® Ointment) for the treatment of genital warts has been assessed positively by the national regulatory authorities of ...
-
MediGene Concludes Agreement with Juste for the Commercialization of Veregen in Spain and Portugal
(25 Jun 2009)
MediGene to receive milestone payments totalling up to 2,550,000 euro and royalties on future sales
MediGene AG has entered into a marketing partnership with the Spanish company Juste S.A.Q.F. for the commercialization of Veregen® ointment (formerly Polyphenon E®) in Spain and Portugal. Juste will promote and distribute the drug for the treatment ...
-
FDA Grants Orphan Drug Designation for MediGene's Drug Candidate EndoTAG(TM)-1
(25 May 2009)
Orphan drug designation ensures market exclusivity for a period of seven years following market approval
MediGene AG has obtained orphan drug designation from the US regulatory authority FDA (US Food and Drug Administration) for paclitaxel, the active ingredient in MediGene's drug candidate EndoTAG(TM)-1 for the indication pancreatic cancer. Orphan ...
|
|
|
|
|
Top